CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

BACKGROUND: Acute myeloid leukemia (AML) remains a difficult disease to treat and requires new therapies to improve treatment outcome. Wee1 inhibitors have been used to prevent activation of the G2 cell cycle checkpoint, thus enhancing the antitumor activity of DNA damaging agents. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Wenxiu, Xie, Chengzhi, Li, Chunhuai, Caldwell, J Timothy, Edwards, Holly, Taub, Jeffrey W, Wang, Yue, Lin, Hai, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237862/
https://www.ncbi.nlm.nih.gov/pubmed/25084614
http://dx.doi.org/10.1186/s13045-014-0053-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237862/
https://www.ncbi.nlm.nih.gov/pubmed/25084614
http://dx.doi.org/10.1186/s13045-014-0053-9

Ejemplares similares